Tranzyme (TZYM) was a very promising drug in Phase2 lots of cash , big investment bankers. Big insider and Instity owners 27 M shares.A sure bet around 4 dollars most in for and then today Tranzyme, Inc. (TZYM) trial failure.
tears in my beer.
Possibly you attach a different meaning to the rest of us to the term "very promising drug" -
"Tranzyme Pharma ( TZYM ) announced it is discontinuing and immediately ending patient enrollment in DIGEST, a Phase 2b trial in diabetic patients receiving TZP-102 for the management of symptoms of gastroparesis, due to insufficient efficacy.
Tranzyme Pharma said its decision followed a planned interim futility analysis, which examined patients' responsiveness to thrice daily oral dosing of 10mg of TZP-102 or placebo at the end of weeks 4 and 8 of a 12 week trial. The results are consistent with the findings of a prior Phase 2b trial in that there was a very large placebo effect and no treatment effect."